OK, I'll go out on a limb. First, let me say that it's been about six months since I've had any contact with Donna Nichols or with other AGPH personnel.
I also need to say that, with Peter's description of the Q&A session, I'm kicking myself for not freeing up time for the conference call.
Put the two together, and I'm flying blind.
I think that the phrase "tracking stock" may be overworked here. We'll see. I feel that it will be a separate company, spinning off cancer to shareholders as a dividend.
Some have already written to me, asking if I was disappointed with the oncology-related announcement. I see this as the first disclosure in an attempt to care for the shareholder. I had earlier indicated that a Chiron-like deal might be in the offing. If oncology is spun out to shareholders, we retain a larger percentage of the potential upside if a portion of the company goes in a CHIR-like deal.
One other factor to consider..... the Ciba/Chiron deal has not proven to be as successful as the Genentech model. Johnson et al. are running the company as Genentech was run, socking profit back into R&D. Just a thought, although I believe that, given Johnson's brains and drive, the Chiron model would be a more profitable fit for all parties involved.
Now that I've made a complete fool of myself, I surrender the soap box. It's just too absurd to have that great sales force out there without Sustiva (when and if approved) or other products in-hand to complement nelf.
Rick |
